Google Analytics counts our visits, with cookies. No thanks turns it off and removes its cookies; in Europe, the UK, Switzerland and India, or wherever we cannot tell where you are, it stays off unless you accept. Cookie Notice

Advertise
PRICES
BTCETHSOLXRPBNBTONDOTLTCPOLHBARNEARARBUNI

← Back to NewsDesk

AI summary of a third-party reportNeutralNewsDesk

OpenAI buys Orchestra Bio to add drug programme agents to Rosalind

OpenAI has acquired Orchestra Bio, a San Francisco startup whose AI agents track drug development programmes, and will fold its team and platform into its Rosalind life sciences suite. Terms were not disclosed.

Why it matters: OpenAI and Anthropic are both buying into the workflow behind new medicines, a sign that AI labs see drug development as a commercial market beyond subscriptions.

InvestIn.News NewsDesk · 1 min read
Share
Picture from Decrypt for: OpenAI buys Orchestra Bio to add drug programme agents to Rosalind
Image: Decrypt
Original reporting: Jose Antonio Lanz, Decrypt

Key points

  • Orchestra's agents map how setbacks such as a failed manufacturing batch affect a drug programme and compare responses, with scientists making the final call.
  • OpenAI says bringing a drug to US approval can take up to 15 years and cost more than $2.6bn, with fewer than 10% of candidates succeeding.

The financial terms were not disclosed.

Fewer than 10% of candidates that enter human testing reach pharmacy shelves. Drug teams must also coordinate internal departments and outside partners such as contract research organisations and contract manufacturers, often on systems that do not connect.

Orchestra's agents are designed to work out which activities and deadlines are affected when something goes wrong, gather relevant information and compare possible responses. Scientists and programme leaders still make the final decision.

OpenAI launched GPT-Rosalind in April for vetted US enterprise customers including Amgen and Moderna, and a companion product called Rosalind Workbench. The acquisition follows Anthropic's roughly $400m purchase of Coefficient Bio in April and its June launch of Claude Science.

What to watch: OpenAI has not said when Orchestra's agents will appear inside Rosalind.

Read the full story on Decrypt

Live updates on NewsFeeds:AIDesk editor: Keshav Aggarwal (accountable for this page; this summary was not edited by hand)

How this was produced: an AI model wrote this summary of Decrypt’s report, which we credit and link above. Read our Editorial and AI policy. Spotted a mistake? See Corrections.

Not investment advice. Read the risk disclaimer.

← Back to NewsDesk